Welcome to the Working Group on New TB Drugs Blog
Watch Video from the World TB Day Congressional Briefing
A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Links to video included.
Death of TB Champion, Rep. Donald Payne
U.S. Representative Donald Payne from New Jersey died Tuesday, March 6. He will be remembered as a great champion of TB as well as malaria and HIV/AIDS.
TB R&D Weekly Update: CSU Identifies Anti-TB Compound against Unique Target
This week’s article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–that inhibits an essential cell function of the mycobacteria. Additional links to TB R&D News are included.
News from the TB Treatment Field
Recent articles from around the globe related to governments addressing problems with providing treatment services to those with tuberculosis
Stop TB Partnership’s Coordinating Board Meets in DC
Today was the opening of the 2-day Stop TB Partnership’s Coordinating Board (CB) meeting in Washington, D.C. which included welcoming remarks by Dr. Rajiv Shah (Administrator, USAID), Ms. Lois Quam (Executive Director, GHI), and Dr. Howard Koh (Assistant Secretary, U.S. Depart. of HHS).
Public Sector Has Significant Role in Drug Development
With government budget shortfalls and looming funding cuts, priorities across the public sector are being scrutinized especially with relation to scientific and medical research which represents only 2% of the total federal budget in the U.S. This month, two articles published in separate journals by different groups with different objectives address the role of the public sector in the development of pharmaceuticals. Both articles found that the public sector does have impact in this area especially for innovative drugs and biologics.
FDA Streamlines Review for Drug Combinations
The FDA issued a draft guidance for the drug industry entitled “Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination.” This is exciting news for TB drug development, since there is the potential to reduce the time to develop and obtain approval for new regimens by several years. The FDA is accepting comments from the public until February 14, 2011.
Duke Students Study TB Control in Rural North Carolina
“When I told my friends about my summer plans, many were surprised to hear that tuberculosis still existed in the US, not to mention, right here in North Carolina,” writes Duke University senior Catherine Castillo in her first blog post as an intern at the Wake County Tuberculosis Program.
-
Toppix TB News- Effect of Isoniazid Shortage on TB Care 24 May 2013
- Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 23 May 2013
- Impact of a Shortage of First-Line Antituberculosis Medication on... 23 May 2013
- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
